开云网页登录_开云app官网入口下载苹果版

Abstract

CLC Number:

R593.2

References25

[1]	Schett G, McInnes IB, Neurath MF. Reframing immune-mediated inflammatory diseases through signature cytokine hubs[J]. N Engl J Med, 2021, 385(7):628-639. doi:10.1056/NEJMra1909094 URL
[2]	López-Benjume B, Rodríguez-Pintó I, Amigo MC, et al. Eculizumab use in catastrophic antiphospholipid syndrome(CAPS): Descriptive analysis from the "CAPS Re-gistry"[J]. Autoimmun Rev, 2022, 21(4):103055. doi:10.1016/j.autrev.2022.103055 URL
[3]	Chandwar K. Avacopan for the treatment of ANCA-associated vasculitis[J]. N Engl J Med, 2021, 384(21):e81. doi:10.1056/NEJMc2104672 URL
[4]	Azoulay E, Russell L, van de Louw A, et al. Diagnosis of severe respiratory infections in immunocompromised patients[J]. Intensive Care Med, 2020, 46(2):298-314. doi:10.1007/s00134-019-05906-5pmid:32034433
[5]	Bechman K, Halai K, Yates M, et al. Nonserious infections in patients with rheumatoid arthritis: results from the british society for rheumatology biologics register for rheumatoid arthritis[J]. Arthritis Rheumatol, 2021, 73(10):1800-1809. doi:10.1002/art.41754 URL
[6]	Greenberg JD, Reed G, Kremer JM, et al. Association of methotrexate and tumour necrosis factor antagonists with risk of infectious outcomes including opportunistic infections in the CORRONA registry[J]. Ann Rheum Dis, 2010, 69(2):380-386. doi:10.1136/ard.2008.089276pmid:19359261
[7]	Gottlieb AB, Deodhar A, Mcinnes IB, et al. Long-term safety of secukinumab over five years in patients with moderate-to-severe plaque psoriasis, psoriatic arthritis and ankylosing spondylitis: update on integrated pooled clinical trial and post-marketing surveillance data[J]. Acta Derm Venereol, 2022, 102:adv00698.
[8]	Saunte DM, Mrowietz U, Puig L, et al. Candida infections in patients with psoriasis and psoriatic arthritis treated with interleukin-17 inhibitors and their practical management[J]. Br J Dermatol, 2017, 177(1):47-62. doi:10.1111/bjd.15015pmid:27580411
[9]	Stone JH, Merkel PA, Spiera R, et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis[J]. N Engl J Med, 2010, 363(3):221-232. doi:10.1056/NEJMoa0909905 URL
[10]	Iwata S, Saito K, Hirata S, et al. Efficacy and safety of anti-CD20 antibody rituximab for patients with refractory systemic lupus erythematosus[J]. Lupus, 2018, 27(5):802-811. doi:10.1177/0961203317749047pmid:29308726
[11]	国家神经疾病医学中心, 国家传染病医学中心, 上海市医学会神经内科专科分会, 等. 抗CD20单克隆抗体治疗神经免疫相关疾病期间感染管理上海专家建议(2022)[J]. 中国临床神经科学, 2022, 30(1):1-7.
	National Center for Neurological Disorders, National Medical Center for Infectious Diseases, Shanghai Medical Association Branch of Neurology, et al. Expert consensus on infection management for Anti-CD20 monoclonal antibody for the treatment of neuroimmune diseases(2022)[J]. Chin J Clin Neurosci, 2022, 30(1):1-7.
[12]	Md Yusof MY, Vital EM, McElvenny DM, et al. Predic-ting severe infection and effects of hypogammaglobulinemia during therapy with rituximab in rheumatic and musculoskeletal diseases[J]. Arthritis Rheumatol, 2019, 71(11):1812-1823. doi:10.1002/art.40937 URL
[13]	Konar M, Granoff DM. Eculizumab treatment and impaired opsonophagocytic killing of meningococci by whole blood from immunized adults[J]. Blood, 2017, 130(7):891-899.
[14]	Bechman K, Subesinghe S, Norton S, et al. A systematic review and meta-analysis of infection risk with small molecule JAK inhibitors in rheumatoid arthritis[J]. Rheumatology (Oxford), 2019, 58(10):1755-1766. doi:10.1093/rheumatology/kez087pmid:30982883
[15]	Olivera PA, Lasa JS, Bonovas S, et al. Safety of Janus kinase inhibitors in patients with inflammatory bowel di-seases or other immune-mediated diseases: a systematic review and meta-analysis[J]. Gastroenterology, 2020, 158(6):1554-1573,e12. doi:S0016-5085(20)30011-1pmid:31926171
[16]	Li J, Yu Y, Xie J, et al. Cryptococcal pneumonia in a patient with rheumatoid arthritis treated with baricitinib[J]. Rheumatology (Oxford), 2021, 61(1):e6-e7.
[17]	Valor-Méndez L, Voskens C, Rech J, et al. Herpes simplex infection in a patient with rheumatoid arthritis treated with baricitinib: a case report[J]. Rheumatology (Oxford), 2021, 60(4):e122-e123.
[18]	Furer V, Rondaan C, Heijstek MW, et al. 2019 update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases[J]. Ann Rheum Dis, 2020, 79(1):39-52. doi:10.1136/annrheumdis-2019-215882 URL
[19]	Allen V, Longley N. Infections in immunosuppressed travellers with autoimmune inflammatory diseases-a narrative review and advice for clinical practice[J]. Rheumatology (Oxford), 2021, 60(9):3969-3976. doi:10.1093/rheumatology/keab445 URL
[20]	Friedman MA, Winthrop KL. Vaccines and disease-modi-fying antirheumatic drugs: practical implications for the rheumatologist[J]. Rheum Dis Clin North Am, 2017, 43(1):1-13. doi:10.1016/j.rdc.2016.09.003 URL
[21]	Medeiros-Ribeiro AC, Bonfiglioli KR, Domiciano DS, et al. Distinct impact of DMARD combination and monotherapy in immunogenicity of an inactivated SARS-CoV-2 vaccine in rheumatoid arthritis[J]. Ann Rheum Dis, 2022, 81(5):710-719. doi:10.1136/annrheumdis-2021-221735pmid:35135832
[22]	Li J, Li J, Yu Y, et al. Pneumocystis pneumonia and rheumatic disease: diagnostic potential of circulating microbial cell-free DNA sequencing[J]. Rheumatol Adv Pract, 2021, 6(1):rkab105.
[23]	Cantini F, Nannini C, Niccoli L, et al. Guidance for the management of patients with latent tuberculosis infection requiring biologic therapy in rheumatology and dermato-logy clinical practice[J]. Autoimmun Rev, 2015, 14(6):503-509. doi:10.1016/j.autrev.2015.01.011 URL
[24]	Galli M, Antinori S, Atzeni F, et al. Recommendations for the management of pulmonary fungal infections in patients with rheumatoid arthritis[J]. Clin Exp Rheumatol, 2017, 35(6):1018-1028.
[25]	Sun F, Chen Y, Wu W, et al. Varicella zoster virus infections increase the risk of disease flares in patients with SLE: a matched cohort study[J]. Lupus Sci Med, 2019, 6(1):e000339. doi:10.1136/lupus-2019-000339 URL

RichHTML

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References25

Related Articles15

Recommended Articles

Metrics

Comments

[1]	DIAO Xuehong, SHEN Yan, CHEN Lin, ZHAN Jia, FANG Liang, CAI Jianfei, CHEN Yue.Application of superb microvascular imaging technology in diagnosing rheumatoid arthritis in the clinical remission stage[J]. Journal of Diagnostics Concepts & Practice, 2022, 21(05): 575-580.
[2]	.[J]. Journal of Diagnostics Concepts & Practice, 2022, 21(03): 304-311.
[3]	ZHANG Hao, CHI Huihui, SU Yutong, YANG Chengde.Study on advances in the association between autoantibodies and clinical phenotypes in idiopathic inflammatory myopathy[J]. Journal of Diagnostics Concepts & Practice, 2022, 21(03): 408-414.
[4]	LU Hongyu, GU Jun, WANG Jing, CAO Yafeng, SONG Luxi, FAN Jun, CHEN Mei.Sjögren′s syndrome secondary to cryptococcal meningoencephalitis: a case report and literature review[J]. Journal of Diagnostics Concepts & Practice, 2021, 20(05): 456-461.
[5]	.[J]. Journal of Diagnostics Concepts & Practice, 2021, 20(01): 8-14.
[6]	.[J]. Journal of Diagnostics Concepts & Practice, 2021, 20(01): 98-103.
[7]	.[J]. Journal of Diagnostics Concepts & Practice, 2019, 18(1): 113-116.
[8]	WANG Yanqing, HUANG Wanxue, LIANG Yuanyuan, WU Zhenzhen, WANG Xuan, TANG Jianping.Clinical and laboratory analysis of primary Sjögren′s syndrome complicated with neurological lesions[J]. Journal of Diagnostics Concepts & Practice, 2019, 18(1): 51-55.
[9]	.[J]. Journal of Diagnostics Concepts & Practice, 2019, 18(1): 109-112.
[10]	.[J]. Journal of Diagnostics Concepts & Practice, 2018, 17(05): 616-619.
[11]	.[J]. Journal of Diagnostics Concepts & Practice, 2018, 17(05): 606-610.
[12]	YUAN Yiwei, GU Juanfang, FEI Zhangli, YANG Mingfeng, WANG Yiwen, WANG Hongzhi.Level of programmed cell death factor 5 in patients with active rheumatoid arthritis[J]. Journal of Diagnostics Concepts & Practice, 2018, 17(04): 453-456.
[13]	.[J]. Journal of Diagnostics Concepts & Practice, 2018, 17(03): 244-248.
[14]	.[J]. Journal of Diagnostics Concepts & Practice, 2018, 17(03): 347-351.
[15]	.[J]. Journal of Diagnostics Concepts & Practice, 2018, 17(03): 249-253.